Compare AbCellera Biologics Inc (ABCL) vs Hasbro, Inc. (HAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Hasbro, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Hasbro, Inc. trades at $75.78 (market cap $10.86B). The key difference: Hasbro, Inc. is far larger — about 4.6× AbCellera Biologics Inc's market cap, and Hasbro, Inc. pays a 3.65% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | HAS | |
|---|---|---|
Market Cap | $2.35B | $10.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $105.88 |
52-Week Low | $2.78 | $70.95 |
Enterprise Value | $1.99B | $13.12B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Hasbro (HAS) trades at $76.73, down 4.27% on the day, with a bearish technical signal but oversold RSI readings suggesting potential reversal. The company reported a net loss of $322.4 million in 2025 despite revenue growth to $4.70 billion, with strong earnings beats in recent quarters. Analyst consensus is bullish with a $107.40 price target, while institutional sentiment remains mixed amid high debt levels and profitability challenges.
The outlook hinges on earnings execution and debt management, with upside from Wizards segment growth and digital initiatives. Key risks include sustained negative margins, $3.38 billion long-term debt burden, and consumer discretionary volatility. Near-term catalyst is Q2 2026 earnings on July 21, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
